Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 12-Aug-24 6:48 PM View:  | Adar1 Capital Management, LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 12-Aug-24 | Purchase | 3,000 | $15.88 | $47,647.20 | 2% 141.64K to 144.64K | |
| 12-Aug-24 6:48 PM View: | Adar1 Capital Management, LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 09-Aug-24 | Purchase | 3,000 | $14.89 | $44,678.70 | 2% 138.64K to 141.64K | |
| 30-May-23 4:21 PM View: | Kiritsy Christopher P Director | Pieris Pharmaceuticals, Inc. (PIRS) | 25-May-23 | Private Purchase | 10,000 | $0.85 | $8,500.00 | 100% 10.0K to 20.0K | |
| 16-May-22 8:19 PM View: | Demuth Tim Chief Medical Officer | Pieris Pharmaceuticals, Inc. (PIRS) | 13-May-22 | Private Purchase | 6,000 | $1.71 | $10,260.00 | 100% 0 to 6.0K | |
| 01-Sep-21 4:38 PM View: | Olwill Shane Chief Development Officer | Pieris Pharmaceuticals, Inc. (PIRS) | 30-Aug-21 | Option Exercise | 38,400 | $1.52 | $58,368.00 | 828% 4.64K to 43.04K | |
| 01-Sep-21 4:38 PM View: | Olwill Shane Chief Development Officer | Pieris Pharmaceuticals, Inc. (PIRS) | 30-Aug-21 | Market Option Sale | 38,400 | $5.11 | $196,380.00 | (89%) 43.04K to 4.64K | |
| 22-Jul-20 6:15 PM View: | Aquilo Capital Management, ... 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 21-Jul-20 | Market Sale | 1,900,000 | $2.95 | $5,605,000.00 | (34%) 5.58M to 3.68M | 8% |
| 10-Sep-19 6:00 PM View: | Bvf Partners L P/il 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 06-Sep-19 | Market Sale | 50,000 | $4.50 | $224,970.00 | (1%) 4.98M to 4.93M | 40% |
| 01-Feb-19 11:57 AM View: | Bvf Partners L P/il 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 30-Jan-19 | Disposition (other) | 5,000,000 | -- | -- | (73%) 6.89M to 1.89M | |
| 17-Sep-18 5:42 PM View: | Kiritsy Christopher P Director | Pieris Pharmaceuticals, Inc. (PIRS) | 14-Sep-18 | Market Purchase | 5,000 | $5.11 | $25,525.00 | 100% 5.0K to 10.0K | (47%) |
| 16-May-18 9:08 AM View: | Geraghty James A Director | Pieris Pharmaceuticals, Inc. (PIRS) | 15-May-18 | Market Purchase | 10,000 | $5.75 | $57,500.00 | 100% 10.0K to 20.0K | (53%) |
| 02-May-18 5:13 PM View: | Orbimed Advisors LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 30-Apr-18 | Market Sale | 1,000,000 | $6.35 | $6,350,000.00 | (18%) 5.55M to 4.55M | 57% |
| 15-Feb-18 4:57 PM View: | Orbimed Advisors LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 13-Feb-18 | Market Option Sale | 7,897 | $8.98 | $70,915.10 | (< 1%) 5.56M to 5.55M | 70% |
| 15-Feb-18 4:57 PM View: | Orbimed Advisors LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 13-Feb-18 | Option Exercise | 7,897 | $4.77 | $37,670.80 | < 1% 5.55M to 5.56M | (48%) |
| 04-Jan-18 3:23 PM View: | Orbimed Advisors LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 03-Jan-18 | Market Sale | 1,709,620 | $7.35 | $12,565,700.00 | (24%) 7.26M to 5.55M | 63% |
| 20-Dec-17 5:12 PM View: | Orbimed Advisors LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 18-Dec-17 | Market Option Sale | 147,635 | $5.70 | $841,520.00 | (2%) 7.41M to 7.26M | 52% |
| 20-Dec-17 5:12 PM View: | Orbimed Advisors LLC 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 18-Dec-17 | Option Exercise | 147,635 | $2.09 | $308,052.00 | 2% 7.26M to 7.41M | |
| 17-Aug-17 7:19 PM View: | Reine Allan See Remarks | Pieris Pharmaceuticals, Inc. (PIRS) | 17-Aug-17 | Market Purchase | 20,000 | $4.89 | $97,800.00 | 44% 45.0K to 65.0K | (44%) |
| 17-Aug-17 7:20 PM View: | Geraghty James A Director | Pieris Pharmaceuticals, Inc. (PIRS) | 17-Aug-17 | Market Purchase | 10,000 | $4.82 | $48,200.00 | 100% 0 to 10.0K | (44%) |
| 17-Aug-17 7:19 PM View: | Reine Allan See Remarks | Pieris Pharmaceuticals, Inc. (PIRS) | 16-Aug-17 | Market Purchase | 45,000 | $4.79 | $215,550.00 | 100% 0 to 45.0K | (43%) |
| 09-May-17 6:30 PM View: | Kiritsy Christopher P Director | Pieris Pharmaceuticals, Inc. (PIRS) | 21-Apr-17 | Option Exercise | 5,000 | $1.59 | $7,950.00 | 100% 0 to 5.0K | |
| 15-Jun-16 5:00 PM View: | Matis Louis SVP, Chief Development Officer | Pieris Pharmaceuticals, Inc. (PIRS) | 14-Jun-16 | Market Purchase | 7,915 | $1.71 | $13,534.70 | 380% 2.08K to 10.0K | 61% |
| 15-Jun-16 5:00 PM View: | Matis Louis SVP, Chief Development Officer | Pieris Pharmaceuticals, Inc. (PIRS) | 13-Jun-16 | Market Purchase | 2,085 | $1.68 | $3,502.80 | 100% 0 to 2.08K | 64% |
| 15-Jun-16 5:00 PM View: | Yoder Stephen S. President and CEO Director | Pieris Pharmaceuticals, Inc. (PIRS) | 13-Jun-16 | Market Purchase | 6,000 | $1.68 | $10,080.00 | 100% 0 to 6.0K | 64% |
| 15-Jun-16 5:00 PM View: | Deptula-Hicks Darlene M SVP, Chief Financial Officer | Pieris Pharmaceuticals, Inc. (PIRS) | 13-Jun-16 | Market Purchase | 5,000 | $1.66 | $8,300.00 | 100% 0 to 5.0K | 66% |
| 08-Jul-15 5:45 PM View: | Khuong Chau Quang Director 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 06-Jul-15 | Market Purchase | 500,000 | $2.75 | $1,375,000.00 | 7% 6.76M to 7.26M | (< 1%) |
| 08-Jul-15 5:46 PM View: | Orbimed Advisors LLC Director 10% Owner | Pieris Pharmaceuticals, Inc. (PIRS) | 06-Jul-15 | Market Purchase Duplicate | 500,000 | $2.75 | $1,375,000.00 | 7% 6.76M to 7.26M | (< 1%) |
